Evidence map›Paper›PMID 30827745›Full record

ArticleEuropean journal of cancer (Oxford, England : 1990)2019

Mortality associated with statins in men with advanced prostate cancer treated with androgen deprivation therapy.

Szu-Yuan Wu, Su-Chen Fang, Hung-Jen Shih, Yu-Chin Wen, Yu-Hsuan Joni Shao

Abstract read
PubMed Publisher
In one paragraph

Article in European journal of cancer (Oxford, England : 1990), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
37citing papers in PubMed, 3 pooled it
3.7field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

37 citing papers in PubMed, 3 syntheses or guidelines pooled it, 63 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Article
  6. Review
  7. Article
  8. Article
  9. Targeting lipid metabolism in metastatic prostate cancer.Therapeutic advances in medical oncology · 2023
    Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Statin as a therapeutic agent in gastroenterological cancer.World journal of gastrointestinal oncology · 2022
    Review
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

5 authors at 4 institutions in 3 countries.

Szu-Yuan WuDepartment of Radiation Oncology, Wan Fang Hospital, Taipei Medical University, Taipei, Taiwan; Department of Internal Medicine, School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan; Institute of Clinical Science, Zhongshan Hospital, Fudan University, Shanghai, China.
Su-Chen FangCollege of Nursing, Taipei Medical University, Taipei, Taiwan.
Hung-Jen ShihDepartment of Urology, Wan Fang Hospital, Taipei Medical University, Taipei, Taiwan; School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan.
Yu-Chin WenDepartment of Urology, Wan Fang Hospital, Taipei Medical University, Taipei, Taiwan; School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan.
Yu-Hsuan Joni ShaoGraduate Institute of Biomedical Informatics, Taipei Medical University, Taipei, Taiwan; Department of Epidemiology, Rutgers School of Public Health, Piscataway, NJ, USA; Clinical Big Data Research Center, Taipei Medical University Hospital, Taipei, Taiwan. Electronic address: jonishao@tmu.edu.tw.
Taipei Medical University Hospital · TWRutgers, The State University of New Jersey · USSun Yat-sen University · CNTaipei Medical University · TW

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesBefore launching large clinical trials to confirm the effects of statins in improving outcomes among men with prostate cancer (PC), the most appropriate target patient population and the type of statins need to be clearly identified. PATIENTS AND

methodsA retrospective cohort study was conducted using the Taiwan Cancer Registry of 2008-2014. This study included 5749 men with locally advanced and metastatic PC who received only androgen deprivation therapy (ADT) in the first year after their cancer diagnosis. Statin users were defined as anyone who was prescribed statins for >28 days. An inverse probability of treatment-weighted Cox model was used to estimate the effects of statin use on all-cause mortality and PC-specific mortality (PCSM) while treating the statin status as a time-dependent variable.

resultsOverall, 2259 patients died, and 1495 of them died of PC during a median follow-up of 3.6 years from 1 year after their diagnosis. Statin use was associated with significant reductions in all-cause mortality (hazard ratio [HR] = 0.78, 95% confidence interval [CI]: 0.70-0.86) and PCSM (HR = 0.76, 95% CI: 0.68-0.86) for metastatic disease and all-cause mortality (HR = 0.66, 95% CI: 0.54-0.81) for locally advanced disease. Patients who received atorvastatin, pravastatin, rosuvastatin or pitavastatin showed a stronger reduction in mortality than those who received other statins. Benefits of statins were consistently observed in men who received post-diagnostic statins, even in those with high comorbidities or an old age.

conclusionsOur results suggest that only atorvastatin, pravastatin and rosuvastatin were associated with improved survival in advanced PC patients receiving ADT.

Indexed as

AgedAndrogen AntagonistsCause of DeathDisease ProgressionFollow-Up StudiesHormone Replacement TherapyHumansHydroxymethylglutaryl-CoA Reductase InhibitorsMaleProportional Hazards ModelsProstatic NeoplasmsRetrospective StudiesTaiwanAndrogen AntagonistsHydroxymethylglutaryl-CoA Reductase InhibitorsADTMetastasisMortalityProstate cancerStatin

Identifiers

PMID30827745
OpenAlexW2918169911

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.